Tirzepatide(LuciTir)

In May 2022, the FDA approved tirzepatide (Mounjaro) as a prescription medication for the treatment of type 2 diabetes in adults. The drug targets both the glucose-dependent insulinotropic polypeptide receptor (GIP‑R) and the glucagon-like peptide‑1 receptor (GLP‑1R). It should be used strictly under medical supervision.

Lucius Related Certificates

Drug Inspection Report

Drug Inspection Report

Drug Approval Certificate

Drug Approval Certificate

Mechanism of Action

Dual agonist of glucose-dependent insulinotropic polypeptide receptor (GIP-R) and glucagon-like peptide-1 receptor (GLP-1R)

Dosage and Administration

Route and frequency of Tirzepatide administration: Once weekly.

The dose of Tirzepatide should be adjusted according to the patient's individual condition. Please consult your physician for specific guidance.

Recommended reading: Dosage and Administration of Tirzepatide

Side Effects

Common side effects: Nausea, diarrhea, decreased appetite, etc.

Serious side effects: Acute pancreatitis, allergic reactions, etc.

Reference article: Side Effects of Tirzepatide

Use in Special Populations

Pregnancy: Fetal exposure to Tirzepatide may pose a risk. Use only if the potential benefit justifies the potential risk to the fetus.

Lactation: There are no data on the presence of Tirzepatide in human milk, the effects on the breastfed infant, or the effects on milk production.

Daily Precautions

1. Tirzepatide causes thyroid C-cell tumors in rats. The human relevance of this finding has not been determined. Patients should inform their healthcare provider if they experience symptoms of thyroid tumors (e.g., a lump in the neck, persistent hoarseness, dysphagia, or dyspnea).

2. There is a potential risk of pancreatitis. If pancreatitis is suspected (severe abdominal pain that may radiate to the back, with or without vomiting), discontinue Tirzepatide immediately and contact your healthcare provider.

3. Inform patients that the risk of hypoglycemia is increased when Tirzepatide is used in combination with insulin secretagogues (such as sulfonylureas) or insulin. Educate patients on the signs and symptoms of hypoglycemia.